Viruses are obligatory intracellular parasites, whose replication depends on pathways and functions of the host cell. Consequently, it is difficult to define virus-specific functions as suitable targets for anti-infective therapy. However, significant progress has been made in the past 50 years towards the development of effective and specific antivirals. In particular, human immunodeficiency virus, hepatitis C virus, and hepatitis B virus, which cause chronic infections affecting millions of individuals world-wide, are a major focus of antiviral research. Initially, antivirals were mainly directed against virus-specific enzymes; more recently, drugs inhibiting the steps of virus entry or release have been developed. Rational approaches towards drug development, based on information about structure and function of viral proteins and molecular mechanisms of virus-host interactions, have become increasingly successful. Novel strategies currently explored in basic research or preclinical studies include approaches targeting host factors important for virus replication, the exploitation of the innate immune response system as well as the use of gene silencing strategies aimed at interfering with viral gene expression. Today, a number of effective virostatics targeting various viral replication steps are approved for treatment of important viral diseases. However, the use of these drugs is limited by the rapid development of antiviral resistance, which represents a central problem of current antiviral therapy.
Chapter PDF
Similar content being viewed by others
Keywords
- Antiviral Therapy
- Severe Acute Respiratory Syndrome
- Antiviral Drug
- Severe Acute Respiratory Syndrome
- Antiviral Resistance
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Allaway GP (2006) Development of Bevirimat (PA-457): first-in-class HIV maturation inhibitor. Retrovirology 3(Suppl 1):S8
Alymova IV, Taylor G, and Portner A (2005). Neuraminidase inhibitors as antiviral agents. Current drug targets 5:401–409
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (2003). Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science (New York, N.Y 300:1763– 1767
Baltimore D (1971) Expression of animal virus genomes. Bacteriol Rev 35:235–241
Baltimore D (1988) Gene therapy. Intracellular immunization. Nature 335:395–396
Bauer DJ (1985) A history of the discovery and clinical application of antiviral drugs. Br Med Bull 41:309–314
Bauer DJ, Stvincent L, Kempe CH, Downie AW (1963) Prophylactic treatment of small pox contacts with N-methylisatin beta-thiosemicarbazone (Compound 33t57, Marboran). Lancet 35:494–496
Berkhout B (2004) RNA interference as an antiviral approach: targeting HIV-1. Curr Opin Mol Ther 6:141–145
Bieniasz PD (2006) Late budding domains and host proteins in enveloped virus release. Virology 344:55–63
Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, Air GM (1993) Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol 232:1069–1083
Bourne CR, Finn MG, Zlotnick A (2006) Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol 80:11055–11061
Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J, Elledge SJ (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921–926
Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–894
Bunka DH, Stockley PG (2006) Aptamers come of age — at last. Nat Rev 4:588–596
Damm EM, Pelkmans L (2006) Systems biology of virus entry in mammalian cells. Cell Microbiol 8:1219–1227
De Clercq E, Descamps J, De Somer P, Holy A (1978) (S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 5:563–565
De Clercq E, Holy, A (2005) Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nature reviews 4:928–940
Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J et al. (2003) Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299:893–896
Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74:5716–5720
Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM et al. (2001) Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). Aids 15:1951–1957
Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB et al. (2005a) Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 192:30–36
Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB et al. (2005b) Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. Aids 19:2167–2169
Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, Musoke P et al. (2006) Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 42:610–613
Foy LiK, Sumpter R, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M Jr (2005) Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS 102:2986–2991
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 347:975–982
Galiana-Arnoux D, Dostert C, Schneemann A, Hoffmann JA, and Imler JL (2006). Essential function in vivo for Dicer-2 in host defense against RNA viruses in drosophila. Nature immunology 7:590–597
Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, Chi JT, Braich R, Manoharan M, Soutschek J, Ohler U, Cullen BR (2007) A viral microRNA functions as an orthologue of cellular miR-155.Nature 450:1096–1099
Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proceedings of the National Academy of Sciences of the United States of America 99:15655– 15660
Gripon P, Cannie I, Urban S (2005). Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 79:1613–1622
Harris RS, Liddament MT (2004) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4:868–877
Haasnoot J, Berkhout B (2006) RNA interference: its use as antiviral therapy. Handb Exp Pharmacol 173:117–150
Hamre D, Brownlee KA, Donovick R (1951) Studies on the chemotherapy of vaccinia virus. II. The activity of some thiosemicarbazones. J Immunol 67:305–312
Hengel H, Koszinowski UH, Conzelmann KK (2005) Viruses know it all: new insights into IFN networks. Trends Immunol 26:396–401
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126
Hoofnagle JH, Seeff LB (2006) Peginterferon and ribavirin for chronic hepatitis C. New Engl J Med 355:2444–2451
Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH (2000). Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. Aids 14:F111–F115
Johnson CL, Gale M Jr (2006) CARD games between virus and host get a new player. Trends Immunol 27:1–4
Kielian M, Rey FA (2006) Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 4:67–76
Lai L, Han X, Chen H, Wei P, Huang C, Liu S, Fan K, Zhou L, Liu Z, Pei J et al. (2006) Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase. Curr Pharm Des 12:4555–4564
Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, Johnston E, Wells J, Shetty AK, Coovadia H et al. (2005) Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis 192:1260–1264
Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM et al. (2003) PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 100:13555–13560
Li F, Wild C (2005) HIV-1 assembly and budding as targets for drug discovery. Curr Opin Investig Drugs 6:148–154
Li XD, Sun L, Seth RB, Pineda G, Chen ZJ (2005) Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 102:17717–17722
Lilly F (1967) Susceptibility to two strains of Friend leukemia virus in mice. Science 155:461–462
Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA et al. (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714–1722
Luban J (2007) Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 81:1054–1061
Ludwig S (2007) Influenza viruses and MAP kinase cascades – novel targets for antiviral intervention. Signal Transduction 7:81–88
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with in-terferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965
Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087–5094
Matzen K, Elzaouk L, Matskevich AA, Nitzsche A, Heinrich J, Moelling K (2007) RNase H-mediated retrovirus destruction in vivo triggered by oligodeoxynucleotides.Nat Biotechnol 25:669–674
Medawar PB, Medawar JS (1983) Viruses. In: Medawar PB, Medawar JS (eds) Aristotle to zoos: a philosophical dictionary of biology. Harvard University Press, Cambridge, MA p. 275
Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167–1172
Müller B, Kräusslich HG (2008) Antiviral drugs. In: Offermanns u. Rosenthal (ed) Encyclopedic reference of molecular pharmacology, 2nd ed. Springer Verlag, Heidelberg
Münch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T et al. (2007) Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129:263–275
Nisole S, Stoye JP, Saib A (2005). TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3:799–808
Pelkmans L, Fava E, Grabner H, Hannus M, Habermann B, Krausz E, Zerial M (2005) Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature 436:78–86
Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26:335–341
Pornillos O, Garrus JE, Sundquist WI (2002) Mechanisms of enveloped RNA virus budding. Trends Cell Biol 12:569–579
Ray N, Doms RW (2006). HIV-1 coreceptors and their inhibitors. Current topics in microbiology and immunology 303:97–120
Seth RB, Sun L, Chen ZJ (2006) Antiviral innate immunity pathways. Cell research 16:141–147
Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, Stevens L, Heymann SJ, Ndung'u T, Gaseitsiwe S et al. (2006) Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. Aids 20:1281–1288
Sieczkarski SB, Whittaker GR (2005) Viral entry. Curr Top Microbiol Immunol 285:1–23
Snell NJ (2001). Ribavirin—current status of a broad spectrum antiviral agent. Expert opinion on pharmacotherapy 2:1317–1324
Steeves R, Lilly F (1977) Interactions between host and viral genomes in mouse leukemia. Ann Rev Genetics 11:277–296
Sticht J, Humbert M, Findlow S, Bodem J, Muller B, Dietrich U, Werner J, Krausslich HG (2005) A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 12:671–677
Stockman LJ, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3:e343
Taylor JM, Quilty D, Banadyga L, Barry M (2006) The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax. The Journal of biological chemistry 281:39728–39739
ter Brake O, Konstantinova P, Ceylan M, Berkhout B (2006) Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 14:883–892
von Laer D, Hasselmann S, Hasselmann K (2006) Gene therapy for HIV infection: what does it need to make it work? J Gene Med 8:658–667
Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, A. Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature medicine 11:791–796
Wang XH, Aliyari R, Li WX, Li HW, Kim K, Carthew R, Atkinson P, Ding SW (2006) RNA interference directs innate immunity against viruses in adult Drosophila. Science 312:452–454
Waterhouse PM, Wang MB, Lough T. (2001). Gene silencing as an adaptive defence against viruses. Nature 411:834–842
Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–122
Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A et al. (2005) Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192:958–966
Wilkins C, Dishongh R, Moore SC, Whitt MA, Chow M, Machaca K (2005) RNA interference is an antiviral defence mechanism in Caenorhabditis elegans. Nature 436:1044–1047
Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK (2008) A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol 378:565–580
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Müller, B., Kräusslich, HG. (2009). Antiviral Strategies. In: Kräusslich, HG., Bartenschlager, R. (eds) Antiviral Strategies. Handbook of Experimental Pharmacology, vol 189. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79086-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-540-79086-0_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79085-3
Online ISBN: 978-3-540-79086-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)